Rank #1: A systematic review of isolated colonic Crohn's disease: the third IBD?
Full paper >> http://gut.bmj.com/content/66/2/362
Feb 27 2017
Rank #2: Bifidobacterium and gastrointestinal inflammation
Liam O’Mahony (Swiss Institute of Allergy and Asthma Research) talks to Mairi McLean (senior clinical lecturer and consultant in gastroenterology at the University of Aberdeen) about his paper looking at Bifidobacterium infantis’s interaction with T cells, and the bacterium’s potential to protect against gastrointestinal inflammation.
Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells (http://tinyurl.com/b6xnnsx)
Feb 21 2013
Rank #3: Antibiotics as deep modulators of gut microbiota: between good and evil.
Jan 04 2017
Rank #4: Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease
Full text > http://gut.bmj.com/content/65/5/767.full
Jun 17 2016
Rank #5: Amniotic stem cell treament for necrotic enterocolitis
Necrotising enterocolitis (NEC) remains one of the primary causes of morbidity and mortality in neonates and alternative strategies are needed. Stem cells have become a therapeutic option for other intestinal diseases, which share some features with NEC.
Along with colleagues, Simon Eaton and Paolo De Coppi, both from University College London Institute of Child Health, have tested the hypothesis that amniotic fluid stem (AFS) cells exerted a beneficial effect in a neonatal rat model of NEC.
Mairi McLean discusses their findings with them.
Read the full paper:
Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism http://goo.gl/EFUuN0
Feb 21 2014
Rank #6: Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea
Mairi McLean talks to Robin Spiller, NIHR Nottingham Digestive Diseases Biomedical Research Unit, and David Tooth, School of Biomedical Sciences, University of Nottingham, about their paper: Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.
Read the full article: http://goo.gl/0OIP34
Jun 09 2014
Rank #7: Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma
In this track Mairi McLean talks to Hasim El-Serag about the recent paper "Surveillance endoscopy is associated with improved outcomes of oesophagealadenocarcinoma detected in patients with Barrett's oesophagus."
Sep 22 2016
Rank #8: PUFAS and neoplasms
Mairi McLean, Gut education editor, talks to Professor Mark Hull, Leeds Institute of Molecular Medicine, about his research into the action of polyunsaturated fatty acids on the formation of neoplams.
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer (http://tinyurl.com/a7q8co4)
Feb 21 2013
Rank #9: Gut podcast: Treatment of pancreatic fibrosis with siRNA
Fibrosis associated with chronic pancreatitis is an irreversible lesion that can disrupt pancreatic exocrine and endocrine function. Currently, there are no approved treatments for this disease.
In this podcast Mairi McLean, Gut education editor, talks to Professor Yoshiro Niitsu from Sapporo Medical University School of Medicine about his manuscript about the potential for therapeutic use of siRNA in the treatment of pancreatic fibrosis.
Read the full research online:
Oct 22 2013
Rank #10: AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition
They have now published a paper in Gut hypothesising that AIEC instigates chronic inflammation by increasing microbial lipopolysaccharide and flagellin levels, and investigating how AIEC colonisation might instigate colitis in T5KO mice.
Mairi McLean talks to Dr Gerwitz about their findings.
Read the full paper (for free): http://gut.bmj.com/content/63/7/1069.full
Aug 21 2014
Rank #11: Update on basic and clinical aspects of eosinophilic oesophagitis
In this podcast, Mairi McLean talks to Professor Alex Straumann, Swiss EoE Clinic and EoE Research Network, about the basic and clinical insights of EoE gathered during the last few years.
Read Professor Straumann's update on the topic:
Sep 25 2014
Rank #12: Besifovir versus entecavir in Asian patients with chronic hepatitis B
In a study recent published in Gut, Professor Man-Fung Yuen, Department of Medicine, The University of Hong Kong, and colleagues, report the results of viral suppression and safety of two doses of besifovir, with entecavir as a comparator in treatment-naive subjects for 48 weeks.
He talks to Mairi McLean about the findings.
Read the full paper:
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B http://gut.bmj.com/content/63/6/996.full
Aug 15 2014
Rank #13: mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway
Mairi McLean talks to Philip Rosenstiel, Institute of Clinical Molecular Biology, Christian-Albrechts University, Kiel, and Stefan Schreiber, University Hospital Schleswig-Holstein, Kiel, about their paper: mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn’s disease http://bit.ly/11FU0Qw.
Apr 24 2013
Rank #14: BMP-9 interferes with liver regeneration and promotes liver fibrosis
Full paper >> http://gut.bmj.com/content/66/5/939
May 31 2017
Rank #15: Recent advances in clinical practice challenges and opportunities in the management of obesity
Mairi McLean talks to Andres Acosta and Barham K Abu Dayyeh, both Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, about their review on the management of obesity.
Read the full paper: http://goo.gl/V37xaq
Apr 29 2014
Rank #16: Bowel cancer screening in England
Before the UK national bowel cancer screening programmes were implemented, a pilot was set-up in England to see if results from randomised controlled trials could be replicated in the general population. Gut has recently published findings from the third round of this.
Co-author David Weller, Centre for Population Health Sciences–General Practice, University of Edinburgh, UK, talks to Gut’s associate editor William Grady about effectiveness of screening, uptake and its link to ethnicity, and the potential of different methods.
Performance measures in three rounds of the English bowel cancer screening pilot (http://tinyurl.com/afyj365)
Feb 21 2013
Rank #17: British Society of Gastroenterology guidelines on diagnosing and managing Barrett's oesophagus
Gut's education editor Mairi McLean discusses highlights from the guidelines on the diagnosis and management of Barrett's oesophagus with authors Rebecca Fitzgerald and Massimiliano di Pietro, both from the MRC Cancer Unit, University of Cambridge.
Read the full paper here: http://bit.ly/1kkPkVW
Jan 31 2014
Rank #18: Cancer treatment induced gastrointestinal symptoms
In the UK chronic gastrointestinal symptoms after cancer therapies have a similar impact as IBD. However, in contrast to patients with IBD, most of these patients won’t see a gastroenterologist. In this month’s Gut Editor’s Choice the causes of these side effects of cancer treatment are discussed, as well as the benefits of investigation and treatment.
In this podcast Mairi McLean, senior clinical lecturer and consultant in gastroenterology at the University of Aberdeen talks to some key stakeholders in this issue:
Professor Sir Mike Richards, national clinical director for cancer and end of life care, Department of Health
Jane Maher, chief medical officer for McMillian Cancer Support
Jon Rhodes, professor of gastroenterology and president of the British Society of Gastroenterology
Jervoise Andeyev, consultant gastroenterologist in pelvic radiation disease at the Royal Marsden NHS Trust, London
Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer (http://tinyurl.com/a6krvl8)
Feb 21 2013
Rank #19: Endoscopic improvement of mucosal lesions in patients with ileocolonic Crohn’s disease
Mairi McLean, Gut’s education editor, talks to Xavier Hébuterne, Department of Gastroenterology and Nutrition, Archet Hospital, Nice, and Jean-Frédéric Colombel, Universite Lille Nord de France, about their paper: Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol http://bit.ly/10dtab8.
Apr 24 2013
Rank #20: Intra-tumoural stroma as a predictor of survival in patients with gastric cancer
Mairi McLean talks to Patrick Tan, associate professor, Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School Singapore, and Heike Grabsch, Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, University of Leeds, about their genomic meta-analysis to identify predictors of survival in patients with gastric cancer.
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer http://goo.gl/Rw8lx6
Aug 02 2013